288 related articles for article (PubMed ID: 21641266)
1. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease.
Bardien S; Lesage S; Brice A; Carr J
Parkinsonism Relat Disord; 2011 Aug; 17(7):501-8. PubMed ID: 21641266
[TBL] [Abstract][Full Text] [Related]
2. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
3. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease.
Liu J; Zhou Y; Wang C; Wang T; Zheng Z; Chan P
Parkinsonism Relat Disord; 2012 Feb; 18(2):140-3. PubMed ID: 21924942
[TBL] [Abstract][Full Text] [Related]
4. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
[TBL] [Abstract][Full Text] [Related]
6. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
Kumari U; Tan EK
FEBS J; 2009 Nov; 276(22):6455-63. PubMed ID: 19804413
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
[TBL] [Abstract][Full Text] [Related]
11. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
[TBL] [Abstract][Full Text] [Related]
12. Genetic testing of LRRK2 in Parkinson's disease: is there a clinical role?
Buhat DM; Tan EK
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S54-6. PubMed ID: 24262189
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
[TBL] [Abstract][Full Text] [Related]
14. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
[TBL] [Abstract][Full Text] [Related]
15. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis.
Wu X; Tang KF; Li Y; Xiong YY; Shen L; Wei ZY; Zhou KJ; Niu JM; Han X; Yang L; Feng GY; He L; Qin SY
Parkinsonism Relat Disord; 2012 Jul; 18(6):722-30. PubMed ID: 22575234
[TBL] [Abstract][Full Text] [Related]
17. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA
Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
19. A study of LRRK2 mutations and Parkinson's disease in Brazil.
Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
